Lymphoma Newsletter - February 2026

LymphomaFebruary 2026

Listen: Audio Summary of Key Highlights

Clinical briefing · tap to listen

0:00 / 4:05

Lymphoma — Monthly Compass

Feb 01–28, 2026 • Priority Updates • 3–5 minute read

A curated, practice-minded digest of what moved in lymphoma this month — regulatory signals, clinical development, and the most practice-relevant publications.

Built for oncologists

OncRef Curated Oncology Intelligence Layer

Key Highlights

Practice-Changing Updates
- On February 19, 2026, the FDA approved acalabrutinib plus venetoclax for adults with CLL/SLL, establishing the first all‑oral, fixed‑duration frontline regimen based on AMPLIFY and noting use of the Assessment Aid and orphan drug designation in the review.
- On February 6, 2026, the FDA approved a Yescarta label update removing the prior Limitation of Use in relapsed/refractory primary CNS lymphoma, expanding labeled access to CAR T therapy in this rare setting.
Important Drug Publication Updates
- The 3‑year EPCORE NHL‑1 update reports subcutaneous epcoritamab achieved a 59% ORR and 41% CR with a 36.1‑month median duration of CR and nearly 50% MRD negativity in heavily pretreated R/R LBCL, supporting deep, durable responses.
- A pooled analysis across SEQUOIA, ALPINE, and AU‑003 demonstrates zanubrutinib delivers robust efficacy in del(17p)/TP53‑altered CLL/SLL with superior PFS versus ibrutinib in the relapsed/refractory setting and a favorable discontinuation profile.
Key Clinical Development Updates
- Lyell initiated first patient dosing in the Phase 3 head‑to‑head PiNACLE–H2H trial of ronde‑cel versus approved CD19 CAR‑T therapies in second‑line LBCL, reiterated a 2027 BLA plan for the single‑arm PiNACLE study (3L+), and noted FDA Orphan Drug Designation for a high‑risk LBCL subset.
- Ascentage Pharma secured China CDE IND clearance—following recent U.S. FDA IND clearance—for the BTK degrader APG‑3288, launching a multicenter Phase 1 program that includes relapsed/refractory B‑cell lymphomas.
Important Clinical Trial Publications
- Mosunetuzumab monotherapy produced a 40% ORR and 20% CR with manageable cytokine release syndrome in Richter’s transformation, enabling a subset to bridge to allogeneic transplantation.
- Lisocabtagene maraleucel delivered a 95% ORR with a manageable safety profile in relapsed/refractory marginal zone lymphoma in the TRANSCEND FL phase 2 study.
Key Conference Updates
- At the 2026 Tandem Meetings, durable CAR T outcomes in indolent FL were highlighted with ELARA showing a 5‑year CR of 68.1% and median PFS ~53 months with a post‑36‑month relapse plateau, while TRANSCEND FL’s 3‑year update reported a 94% CR and low grade ≥3 CRS/ICANS supporting outpatient feasibility.
- Epcoritamab‑bysp plus R2 in EPCORE FL‑1 reduced the risk of progression/death by ~80% versus R2 (HR 0.21) with 16‑month PFS of 85.5% versus 40.2% and showed lower low‑grade CRS with three‑step versus two‑step step‑up dosing, enabling outpatient delivery.
Emerging Themes & Macro-Trends
- Second‑line FL is poised to pivot toward bispecific‑plus‑R2 regimens for eligible patients, with CAR T reserved for later lines or high‑risk biology, while CD19‑targeted ADCs gain traction as post‑CAR‑T standards in DLBCL.
- Sponsors are prioritizing outpatient‑amenable, step‑up–optimized regimens and sequencing studies versus CAR T, and centers are investing in community delivery models and survivorship infrastructure to capture durable remissions.

FDA Approvals/Withdrawals

On February 19, 2026, the FDA approved acalabrutinib (Calquence, AstraZeneca) in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the AMPLIFY trial, which demonstrated improved progression-free survival in previously untreated CLL patients without del(17p) or TP53 mutation. The recommended regimen involves up to 14 cycles of acalabrutinib and 12 cycles of venetoclax. The prescribing information includes warnings for serious infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity for acalabrutinib, and tumor lysis syndrome, neutropenia, infections, and embryo-fetal toxicity for venetoclax.¹ (read more)

Clinical Development Regulatory Updates

FDA approved AstraZeneca’s Calquence (acalabrutinib) plus AbbVie/Genentech’s Venclexta (venetoclax) on February 19, 2026 for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, noting use of the Assessment Aid and orphan drug designation in the review. The approval establishes a fixed‑duration, all‑oral regimen based on AMPLIFY for previously untreated patients.¹ (read more)
Genentech announced FDA approval of the Venclexta plus acalabrutinib combination for previously untreated CLL on February 19, 2026, highlighting it as the first and only all‑oral, fixed‑duration regimen intended to provide time off treatment. The company cited data from the Phase 3 AMPLIFY study as the basis for the approval.² (read more)
AbbVie reported on February 20, 2026 that FDA approved its supplemental NDA for VENCLEXTA (venetoclax) plus acalabrutinib in previously untreated CLL, positioning the regimen as the first all‑oral, fixed‑duration option in the front‑line setting. The company emphasized that the approval was supported by the Phase 3 AMPLIFY trial.³ (read more)
Kite (Gilead) disclosed on February 6, 2026 that FDA approved a labeling update for Yescarta (axicabtagene ciloleucel) removing the prior Limitation of Use in relapsed/refractory primary central nervous system lymphoma. The change is based on investigator‑sponsored data and expands labeled access within this rare lymphoma setting.⁴ (read more)
Dana‑Farber Cancer Institute issued a February 9, 2026 update stating its investigator‑initiated research supported FDA’s Yescarta label update for primary CNS lymphoma. The institution underscored that the FDA labeling change removes the prior exclusion and may broaden access to CAR T therapy in eligible R/R PCNSL patients.⁵ (read more)
Lyell Immunopharma announced on February 12, 2026 first patient dosing in the Phase 3 PiNACLE–H2H study of rondecabtagene autoleucel (ronde‑cel) versus approved CD19 CAR‑T therapies in second‑line LBCL. The company reiterated regulatory plans, stating a BLA submission for the pivotal single‑arm PiNACLE study (3L+) is expected in 2027 and noted FDA Orphan Drug Designation for a high‑risk LBCL subset.⁶ (read more)
Caribou Biosciences (Feb 4, 2026) previewed late‑breaking presentations and reiterated that its allogeneic anti‑CD19 CAR‑T vispacabtagene regedleucel (vispa‑cel) holds FDA RMAT, Orphan Drug, and Fast Track designations for B‑cell non‑Hodgkin lymphoma. The company linked these expedited program designations to continued clinical development and upcoming data disclosures.⁷ (read more)
Ascentage Pharma (Feb 5, 2026) announced China CDE IND clearance for BTK degrader APG‑3288 and noted the IND had been cleared by the U.S. FDA shortly beforehand. The multicenter Phase 1 program will include relapsed/refractory hematologic malignancies such as B‑cell lymphomas, signaling cross‑regional IND progress for this lymphoma‑relevant agent.⁸ (read more)

Major Conference Updates

Conference Information

2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; Salt Lake City, Utah; February 4–7, 2026. (read more)
February updates highlight maturing durability of CD19 CAR T cells in indolent lymphoma, accelerating adoption of outpatient bispecific combinations, and renewed interest in ADCs as post–CAR‑T options.

Theme 1: Durable CAR T Remissions Reshaping Indolent FL
- Significance: Multi‑year follow‑up consolidates CAR T as a late‑line strategy that can deliver prolonged disease control, challenging assumptions of inevitable serial relapse. (read more)
- Mechanism insights / clinical impact: CD19‑directed autologous CAR T cells (tisagenlecleucel; lisocabtagene maraleucel) show sustained benefit—ELARA reported a 5‑year CR of 68.1% and median PFS ~53 months with an apparent relapse plateau after 36 months; TRANSCEND FL’s 3‑year update showed CR 94% with low grade ≥3 CRS/ICANS, supporting outpatient feasibility in selected centers. (read more)
- Patient populations affected: Adults with relapsed/refractory follicular lymphoma after ≥2 prior regimens, including high‑risk POD24 and bulky disease subgroups. (read more)
Theme 2: Bispecific+R2 Combinations Move Earlier in FL
- Significance: Fixed‑duration, chemo‑free regimens using CD3×CD20 T‑cell engagers are positioning to redefine second‑line management and expand community‑based delivery. (read more)
- Mechanism insights / clinical impact: In EPCORE FL‑1, epcoritamab‑bysp plus R2 cut risk of progression/death by ~80% vs R2 (HR 0.21); 16‑month PFS 85.5% vs 40.2%. Three‑step step‑up dosing reduced low‑grade CRS vs two‑step, and outpatient administration is emphasized—key differentiators vs cellular therapies. (read more)
- Patient populations affected: Relapsed/refractory follicular lymphoma after ≥1 prior line; settings where inpatient CAR T logistics or CRS management expertise limit access. (read more)
Theme 3: ADCs Extend Options Post–CAR T in DLBCL
- Significance: Evidence synthesis spotlights CD19‑targeted ADCs as practical tools for heavily pretreated disease, including after CAR T failure—a critical gap. (read more)
- Mechanism insights / clinical impact: Loncastuximab tesirine delivers a DNA‑crosslinking PBD payload via CD19, with a February 2026 TCT supplement meta‑analysis evaluating efficacy/safety in DLBCL, including post‑CAR‑T cohorts—supporting use as salvage or bridge. (read more)
- Patient populations affected: Relapsed/refractory DLBCL, especially post‑CAR‑T or CAR‑ineligible patients needing off‑the‑shelf therapy. (read more)
Significance
- Expected clinical or translational readouts: Continued maturation of TRANSCEND FL and ELARA informs curative‑intent counseling; expanding real‑world bispecific implementation data (outpatient step‑up dosing) will refine pathways. (read more)
- Regulatory or policy implications: With epcoritamab‑bysp plus R2 already cleared in 2025, payer/guideline uptake and center credentialing for CRS management will govern adoption velocity in 2026. (read more)
- Potential shifts in standard of care: Second‑line FL may pivot toward bispecific+R2 for eligible patients, reserving CAR T for later lines or high‑risk biology; ADCs gain traction as post‑CAR‑T standards in DLBCL. (read more)
- Strategic implications: Sponsors should prioritize outpatient‑amenable regimens, step‑up safety optimization, and sequencing studies versus CAR T; centers should invest in community delivery models and survivorship infrastructure to capture durable remissions. (read more)

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies. A pooled analysis of the SEQUOIA, ALPINE, and AU-003 trials demonstrates that zanubrutinib provides robust efficacy in high-risk CLL/SLL patients harboring del(17p) and/or TP53 mutations, achieving superior progression-free survival compared to ibrutinib in the relapsed/refractory setting. The treatment maintained a favorable safety profile with low rates of discontinuation, supporting its strategic use in both frontline and relapsed/refractory high-risk populations. (, , )

📋 NCT02343120

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial. Long-term follow-up data indicates that subcutaneous epcoritamab induces deep and durable responses in heavily pretreated patients with relapsed or refractory large B-cell lymphoma, achieving an overall response rate of 59% and a complete response rate of 41%. The median duration of complete response was 36.1 months, and nearly half of the evaluable patients achieved minimal residual disease negativity, suggesting the potential for long-term disease-free survival in this difficult-to-treat cohort. ()

📋 NCT03625037

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation. Mosunetuzumab monotherapy elicited an overall response rate of 40% and a complete response rate of 20% in patients with Richter's transformation to diffuse large B-cell lymphoma, a condition with historically poor outcomes. The therapy was well tolerated with manageable cytokine release syndrome, and durable responses allowed a subset of patients to successfully bridge to allogeneic stem cell transplantation. ()

📋 NCT02500407

Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. A retrospective analysis of the ZUMA-2 trial reveals that prior treatment with ibrutinib, as opposed to acalabrutinib, correlates with enhanced expansion and efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma. Ibrutinib exposure was associated with a T-cell phenotype enriched for T helper 17 cells and effector memory differentiation, which independently predicted better clinical responses. ()

📋 NCT02601313

Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial. In a subgroup analysis of Chinese patients from the Phase 3 ALPINE trial, zanubrutinib demonstrated superior improvements in health-related quality of life compared to ibrutinib, particularly regarding the reduction of fatigue. These patient-reported outcomes corroborate the clinical efficacy data and further support the preference for zanubrutinib in managing relapsed/refractory CLL/SLL in this demographic. ()

📋 NCT03734016

New Publications Related to Drugs in Clinical Trial Development

Here is the summary of recent publications related to lymphoma clinical trials for the period of February 2026:

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. Pivekimab sunirine (PVEK), a CD123 antibody-drug conjugate, demonstrated a composite complete response rate of 75% in frontline blastic plasmacytoid dendritic cell neoplasm (BPDCN) and 14% in relapsed/refractory cases. The safety profile was manageable, with peripheral edema and infusion-related reactions being common, supporting PVEK as a durable therapy for BPDCN. ()

📋 NCT03386513

Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. A Bayesian network meta-analysis indicates that pirtobrutinib monotherapy offers superior progression-free survival compared to ibrutinib in treatment-naïve chronic lymphocytic leukemia. While comparable to second-generation covalent BTK inhibitors, pirtobrutinib represents a valuable future first-line treatment option. ()

📋 NCT05023980

Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. The combination of Venetoclax and Blinatumomab proved safe and feasible in adults with relapsed/refractory or MRD-positive B-cell precursor ALL, achieving high rates of MRD clearance without increased neurotoxicity. The recommended phase II dose was established as Venetoclax 800 mg daily plus standard-dose Blinatumomab. ()

📋 NCT05182385

A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma. This study compared Brentuximab Vedotin (BV)/Nivolumab versus BV/Nivolumab/Ipilimumab in relapsed Hodgkin lymphoma, finding that while the triplet did not significantly improve complete response rates, it showed a signal for improved progression-free survival in patients deferring stem cell transplant. The results support the use of checkpoint-ADC induction prior to autologous stem cell transplantation. ()

📋 NCT01896999

Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. JNJ-80948543, a trispecific antibody targeting CD79b, CD20, and CD3, demonstrated potent cytotoxicity and a favorable cytokine profile in preclinical models of B-cell non-Hodgkin lymphoma. Its dual antigen engagement and low-affinity CD3 design aim to mitigate cytokine release syndrome while preventing antigen escape, supporting ongoing Phase 1 clinical evaluation. ()

📋 NCT05424822

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. Long-term follow-up of the SWOG S0016 trial reveals that CHOP followed by radioimmunotherapy (CHOP-RIT) provided superior 15-year progression-free survival compared to R-CHOP in advanced-stage follicular lymphoma. Cure modeling suggests a subset of patients can achieve cure with CHOP-based chemoimmunotherapy, as relapse rates significantly decline after 15 years. ()

📋 NCT00006721

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma. This study identifies that MYC-mediated repression of the miR-29 family leads to TRAF4 upregulation and increased CD40 signaling in transformed follicular lymphoma (tFL). Lower levels of miR-29 were associated with shorter overall survival in follicular lymphoma patients, highlighting a potential prognostic marker and therapeutic target. ()

📋 NCT00006721

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. A chemotherapy-free regimen of acalabrutinib, lenalidomide, and anti-CD20 antibody (rituximab or obinutuzumab) achieved high rates of molecular complete response and durable survival in treatment-naïve mantle cell lymphoma. The study supports this combination as a feasible, time-limited initial therapy guided by longitudinal minimal residual disease monitoring. ()

📋 NCT03863184

Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma. BMS-986458 is a novel ligand-directed degrader of BCL6 that induces rapid degradation of the protein and demonstrates significant antitumor efficacy in lymphoma models. Currently in Phase 1/2 trials, this agent represents a potential first-in-class therapeutic strategy for high-risk non-Hodgkin lymphoma driven by BCL6 dysregulation. ()

📋 NCT06090539

Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study. Adding bortezomib and vorinostat to a chemotherapy backbone was evaluated in infants with acute lymphoblastic leukaemia, showing a safety profile consistent with previous studies but significant infectious morbidity. While no dose-limiting toxicities were observed at the highest vorinostat dose, the regimen highlights the continued challenge of managing toxicity in this vulnerable population. ()

📋 NCT02553460

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells. A novel manufacturing platform using cell-derived nanoparticles (CDNPs) enabled the rapid production of IL-18-expressing CD19 CAR T cells for patients with CD19+ malignancies. In a Phase 1 trial, this approach yielded high cell recovery and durable clinical responses without unexpected toxicities, offering a solution for patients with hard-to-manufacture T cells. ()

📋 NCT04684563

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis. A match-adjusted indirect comparison demonstrates that epcoritamab combined with GemOx significantly improves response rates and progression-free survival compared to Rituximab-GemOx in transplant-ineligible relapsed/refractory DLBCL. These findings suggest Epcor-GemOx is a superior therapeutic option for this patient population. ()

📋 NCT04663347

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial. The Pen-RMA regimen, combining penpulimab with chemotherapy, achieved a 95.7% overall response rate and encouraging survival outcomes in newly diagnosed primary CNS lymphoma. The treatment demonstrated a manageable safety profile and high rates of CSF ctDNA clearance, supporting its potential as a first-line strategy. ()

📋 NCT05347641

Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lisocabtagene maraleucel demonstrated a 95% overall response rate and a manageable safety profile in patients with relapsed or refractory marginal zone lymphoma. These results from the TRANSCEND FL study support this CAR T-cell therapy as a highly effective new treatment option for this indication. ()

📋 NCT04245839

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. Relmacabtagene autoleucel (relma-cel) showed a 71.19% objective response rate and durable remissions in heavily pretreated Chinese patients with relapsed/refractory mantle cell lymphoma. The safety profile was manageable, with low rates of severe cytokine release syndrome and neurotoxicity, confirming its efficacy in this population. ()

📋 NCT04718883

Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial. Varnimcabtagene autoleucel (var-cel), using a fractionated dosing strategy, induced deep remissions with undetectable MRD in 84.4% of adults with relapsed/refractory B-cell precursor ALL. The approach resulted in a low incidence of severe cytokine release syndrome and neurotoxicity, supporting its use in hospital-based settings. ()

📋 NCT04778579

Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant. Burixafor combined with G-CSF demonstrated rapid and effective mobilization of CD34+ hematopoietic stem cells in patients with multiple myeloma and lymphoma. The agent's fast kinetics allow for same-day collection, potentially reducing the healthcare burden associated with stem cell transplantation. ()

📋 NCT02104427

Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study. The BNT162b2 COVID-19 vaccine at adult doses (30 μg) was safe and elicited significant T-cell responses in children with acute leukaemia, even during chemotherapy. While humoral responses were lower than in siblings, the robust cellular immunity supports using higher vaccine doses in this immunocompromised pediatric population. ()

📋 NCT04969601

A Phase II Study of 177Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients. A single administration of 177Lu-lilotomab satetraxetan (Betalutin) achieved clinically relevant response rates with a mild toxicity profile in rituximab-refractory follicular lymphoma. The study suggests this radioimmunoconjugate is a viable option for patients unsuitable for more toxic or prolonged therapies. ()

📋 NCT01796171

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy. In a study of people living with HIV and cancer treated with pembrolizumab, a subset of patients showed a reduction in the HIV reservoir associated with early induction of interferon-stimulated genes and antiviral restriction factors. These findings suggest that anti-PD-1 therapy may enhance innate immune pathways contributing to HIV reservoir decay. ()

📋 NCT02595866

Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma. Higher metabolic tumor volume (MTV) at baseline was strongly associated with poorer health-related quality of life (HRQoL) in patients with newly diagnosed classic Hodgkin lymphoma. However, this negative impact on HRQoL did not persist into the second year of recovery, suggesting successful treatment mitigates the initial burden. ()

📋 NCT01356680

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Maintenance therapy with the HDAC inhibitor resminostat significantly prolonged progression-free survival compared to placebo in patients with advanced-stage mycosis fungoides or Sézary syndrome who had achieved disease control. The safety profile was acceptable, with gastrointestinal side effects being the most common, supporting resminostat as a beneficial maintenance strategy. ()

📋 NCT02953301

Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial. The ZUMA-14 trial demonstrated that combining axicabtagene ciloleucel with rituximab yielded a 73% complete response rate and durable responses in refractory large B cell lymphoma. The combination was safe and did not alter CAR T-cell pharmacokinetics, suggesting that dual targeting of CD19 and CD20 is a feasible strategy to limit antigen escape. ()

📋 NCT04002401

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study. A fixed-duration regimen of venetoclax plus obinutuzumab achieved a 90% complete remission rate in Japanese patients with previously untreated CLL or SLL. The safety profile was manageable, with infusion-related reactions and neutropenia being common, confirming the regimen's efficacy in this specific population. ()

📋 NCT05105841

Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma. A cost-effectiveness analysis in the French healthcare setting found that second-line lisocabtagene maraleucel is cost-effective compared to standard of care for relapsed/refractory large B-cell lymphoma. The therapy provided more quality-adjusted life years, supporting its economic value despite higher initial costs. ()

📋 NCT03575351

Clinical Trials Summary

Number of Clinical Trials in lymphoma updated from 2026-02-01 to 2026-02-28:

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Phase 4

Total

Enrolling by Invitation

Not Yet Recruiting

Recruiting

194

Available

Approved for Marketing

Active, Not Recruiting

Completed

Total

120

325

Phase 1 Clinical Trials within 3 Months of Primary Completion Date:

DRUG

NCTID

Status

Clinical Trial Name

Completion Date

CUDC-907

NCT02909777

COMPLETED

Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

2025-12

PF-08046032, Sasanlimab

NCT06870487

ACTIVE_NOT_RECRUITING

An Open-Label Phase 1 Study to Evaluate PF-08046032 as Monotherapy and Part of Combination Therapy in Participants With Advanced Malignancies

2026-02-27

Decitabine + Cedazuridine, Tolinapant

NCT05403450

ACTIVE_NOT_RECRUITING

A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma

2026-03-31

Ceritinib, Docetaxel

NCT03611738

ACTIVE_NOT_RECRUITING

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

2026-04

Phase 2 Clinical Trials within 3 Months of Primary Completion Date:

DRUG

NCTID

Status

Clinical Trial Name

Completion Date

Hypericin

NCT05872854

COMPLETED

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

2025-12-22

LOXO-305

NCT04849416

COMPLETED

A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

2025-12-29

cyclophosphamide, brentuximab vedotin, doxorubicin, prednisone

NCT04569032

COMPLETED

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

2026-01-12

Cyclophosphamide, : Obinutuzumab, Fludarabine Phosphate, Ibrutinib

NCT02629809

ACTIVE_NOT_RECRUITING

First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)

2026-03-31

: Zilovertamab vedotin

NCT05144841

ACTIVE_NOT_RECRUITING

A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)

2026-04-22

Lenalidomide, : Pembrolizumab, : Rituximab

NCT02446457

ACTIVE_NOT_RECRUITING

Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma

2026-04-30

Phase 3 Clinical Trials within 3 Months of Primary Completion Date:

DRUG

NCTID

Status

Clinical Trial Name

Completion Date

: pembrolizumab, : brentuximab vedotin

NCT02684292

COMPLETED

A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

2026-01-14

vinblastine, brentuximab vedotin, bleomycin, doxorubicin, dacarbazine

NCT01712490

COMPLETED

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

2026-02-02

Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises

NCT05894954

COMPLETED

EVANTHEA TRIAL: A Pragmatic, Randomized, Controlled Trial to Evaluate the Effectiveness of a Precision Medicine Treatment Approach for Early Dementia and Mild Cognitive Impairment

2026-02-09

Prednisone, Polatuzumab Vedotin, Rituximab, Vincristine Placebo, Doxorubicin, Cyclophosphamide

NCT03274492

ACTIVE_NOT_RECRUITING

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

2026-04-30

Phase 4 Clinical Trials within 3 Months of Primary Completion Date:

No phase 4 trials completing within the next three months.

NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.